Thabor Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Series A
  • (Cancelled)

  • Investors
  • 2

Thabor Therapeutics General Information

Description

Operator of a biotechnology company intended to develop drugs targeting specifically a new class of proteins involved in the resolution of inflammation. The company develops treatments based on monoclonal antibodies by treating human mucosal inflammatory diseases by inhibiting a target that could be implied in the early inflammatory process and the recruitment of innate immunity cells, enabling healthcare providers to cure their patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 4 Rue Thenard
  • 75005 Paris
  • France
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Corporate Office
  • 4 Rue Thenard
  • 75005 Paris
  • France

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Thabor Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series A) 06-Jul-2022 Cancelled Generating Revenue
2. Seed Round 06-Jul-2022 Completed Generating Revenue
1. Seed Round 20-Sep-2021 $1.18M $1.18M Completed Generating Revenue
To view Thabor Therapeutics’s complete valuation and funding history, request access »

Thabor Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Action 1 Preferance Shares
To view Thabor Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Thabor Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology company intended to develop drugs targeting specifically a new class of proteins involved in
Biotechnology
Paris, France
8 As of 2025

Madison, WI

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Thabor Therapeutics Competitors (46)

One of Thabor Therapeutics’s 46 competitors is Regenerative Medical Solutions, a Venture Capital-Backed company based in Madison, WI.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Regenerative Medical Solutions Venture Capital-Backed Madison, WI
Neurogene Formerly VC-backed New York, NY
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Baliopharm Venture Capital-Backed Basel, Switzerland
Neurelis Venture Capital-Backed San Diego, CA
You’re viewing 5 of 46 competitors. Get the full list »

Thabor Therapeutics Patents

Thabor Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025242680-A1 Humanized anti-agr2 antibody Pending 20-May-2024
WO-2025242685-A1 Optimized anti-agr2 antibody Pending 20-May-2024
EP-4623003-A1 Humanized anti-agr2 antibody Pending 21-Nov-2022
US-20260193331-A1 Humanized anti-agr2 antibody Pending 21-Nov-2022
WO-2024110493-A1 Humanized anti-agr2 antibody Inactive 21-Nov-2022 C07K16/28
To view Thabor Therapeutics’s complete patent history, request access »

Thabor Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Thabor Therapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bpifrance Sovereign Wealth Fund Minority
AdBio partners Venture Capital Minority
To view Thabor Therapeutics’s complete investors history, request access »

Thabor Therapeutics FAQs

  • When was Thabor Therapeutics founded?

    Thabor Therapeutics was founded in 2021.

  • Where is Thabor Therapeutics headquartered?

    Thabor Therapeutics is headquartered in Paris, France.

  • What is the size of Thabor Therapeutics?

    Thabor Therapeutics has 8 total employees.

  • What industry is Thabor Therapeutics in?

    Thabor Therapeutics’s primary industry is Biotechnology.

  • Is Thabor Therapeutics a private or public company?

    Thabor Therapeutics is a Private company.

  • What is Thabor Therapeutics’s current revenue?

    The current revenue for Thabor Therapeutics is .

  • How much funding has Thabor Therapeutics raised over time?

    Thabor Therapeutics has raised $3.28M.

  • Who are Thabor Therapeutics’s investors?

    Bpifrance and AdBio partners have invested in Thabor Therapeutics.

  • Who are Thabor Therapeutics’s competitors?

    Regenerative Medical Solutions, Neurogene, CytomX Therapeutics, Baliopharm, and Neurelis are some of the 46 competitors of Thabor Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process